Politics1 min read

Sanders’ ‘Medicare for All’ plan accrues more liberate and moderate support in Congress

By · Via STAT Health · Published by Everything Blog

In short

Sanders expressed optimism during a Wednesday press conference that Congress could pass legislation lowering the Medicare eligibility age from 65 to 55 while President Trump is still in office. The proposal also aims to expand Medicare to cover dental, vision, and hearing services, while providing guaranteed free Medicaid coverage to children until age 19. Beyond legislative efforts, Sanders indicated plans to investigate the practices of the pharmaceutical and health insurance industries, as well as the actions o…

Key points

  • Sanders expressed optimism during a Wednesday press conference that Congress could pass l…: Sanders expressed optimism during a Wednesday press conference that Congress could pass legislation lowering the Medicare eligibility age from 65 to 55 while President Trump is still in office.
  • The proposal also aims to expand Medicare to cover dental, vision, and hearing services,…: The proposal also aims to expand Medicare to cover dental, vision, and hearing services, while providing guaranteed free Medicaid coverage to children until age 19.
  • Beyond legislative efforts, Sanders indicated plans to investigate the practices of the p…: Beyond legislative efforts, Sanders indicated plans to investigate the practices of the pharmaceutical and health insurance industries, as well as the actions of health secretary Robert F.

Sources checked by our analysis pipeline: 1

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Tons of news coming from the nation’s capitol as Democrats set their agenda for next year, but it’s worth highlighting what else happened yesterday.

Epic officials publicly addressed whether their business practices choke innovation, as detailed in a STAT investigation. What did they say? Scroll down.

As White House pulls Heidi Overton nomination, what’s next for the FDA?

After the White House pulled its nomination of Heidi Overton for commissioner of the Food and Drug Administration on Tuesday evening, the future of the agency that oversees $4.1 trillion worth of food, tobacco, and medical products is extremely unsettled.

The agency’s current acting commissioner, Kyle Diamantas, has reportedly said he’s uninterested in taking the role permanently, and even indicated he doesn’t want to stay at the FDA past the new year. Meanwhile, it is very unlikely that Congress has enough time to install another nominee before January, meaning that Senate Democrats will have final say over the next commissioner.

Who in the…

Politics